Actively Recruiting
Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Led by Chinese University of Hong Kong · Updated on 2024-08-29
260
Participants Needed
2
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Helicobacter pylori infection affects a large portion of the global population and is linked to serious stomach conditions including ulcers and gastric cancer. This research aims to understand the factors that cause pre-cancerous lesions like atrophic gastritis and intestinal metaplasia to progress into cancer. There is also debate on how often and by what methods patients should be monitored, and this study sets up a registry to explore these important clinical questions over time. The study involves a diagnostic procedure called esophagogastroduodenoscopy to collect detailed clinical information on patients with Helicobacter pylori infection, atrophic gastritis, or intestinal metaplasia. Researchers will track patient outcomes, study factors influencing disease progression or regression, and gather data to improve surveillance strategies. Additionally, a biobank will be established to support further research on these stomach conditions. Participants will be followed longitudinally, with evaluations including clinical assessments and data collection to understand risks and outcomes over at least three years. The main focus is on clinical outcomes of patients with H. pylori, along with risk factors for gastric pre-cancerous lesions and cancers. This ongoing observational study will also monitor the effectiveness of surveillance and collect samples for future analysis, with participant involvement including questionnaires and regular reviews.
CONDITIONS
Brief Title
Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years of age or older
- Written informed consent obtained
- Diagnosed with current or past Helicobacter pylori infection
- Histologically proven atrophic gastritis, intestinal metaplasia, dysplasia, or treated gastric cancer
You will not qualify if you...
- Co-morbid illness that prevents endoscopic surveillance
- Declines participation in study questionnaire, biobanking, or regular reviews as per protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At enrollment
Participants undergo esophagogastroduodenoscopy to evaluate clinical features related to Helicobacter pylori infection, atrophic gastritis, and intestinal metaplasia.
1 visit (in-person)
Duration - Up to 3 years
Participants are observed over time to assess the clinical outcomes and progression or regression of pre-neoplastic lesions.
Regular follow-up visits as per protocol
Trial Site Locations
Total: 2 locations
1
Prince of Wales Hospital
Hong Kong, Hong Kong
Actively Recruiting
2
S.H. Ho Centre for Digestive Health, Prince of Wales Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
A
Andrew Ming Yeung HO
T
Thomas Yuen Tung LAM
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here